Xultophy is a single, once-daily injection that combines Tresiba — an insulin degludec injection — and Victoza — a liraglutide injection. The drug, intended to help adults with type 2 diabetes achieve better glycemic control, represents a new class of diabetes treatments.
Novo Nordisk plans to launch Xultophy in the first half of 2017. The drugmaker said it would “work diligently” to ensure the drug is covered on health plans nationwide and will also offer a savings card to help patients lower insurance co-pays, according to a news release.
More articles on supply chain:
DHL Express will invest $185M in US operations to support increased shipping volumes: 3 takeaways
Gartner names top 25 supply chains in healthcare
6 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
